Glaukos COO shares product updates, 2021 pipeline

Conferences|GLAUCOMA 360

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.


See more Glaucoma 360 coverage

Related Videos
ViaLase seeks to disrupt glaucoma treatment paradigm with new femtosecond laser treatment
Related Content

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Modifying and optimizing a new era of glaucoma surgeries

May 31st 2021

Using technology to manage corneal challenges before cataract surgery

March 14th 2023

Adjusting ophthalmology practice to a pandemic

April 19th 2021

Sight Sciences launching new series of surgical system

March 9th 2023

J&J vision receives CE mark approval for new corneal refractive technology

March 1st 2023

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Modifying and optimizing a new era of glaucoma surgeries

May 31st 2021

Using technology to manage corneal challenges before cataract surgery

March 14th 2023

Adjusting ophthalmology practice to a pandemic

April 19th 2021

Sight Sciences launching new series of surgical system

March 9th 2023

J&J vision receives CE mark approval for new corneal refractive technology

March 1st 2023

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Modifying and optimizing a new era of glaucoma surgeries

May 31st 2021

Using technology to manage corneal challenges before cataract surgery

March 14th 2023

Adjusting ophthalmology practice to a pandemic

April 19th 2021

Sight Sciences launching new series of surgical system

March 9th 2023

J&J vision receives CE mark approval for new corneal refractive technology

March 1st 2023
© 2023 MJH Life Sciences

All rights reserved.